Clinical efficacy and safety analysis of combination therapy with trastuzumab, carboplatin and docetaxel in HER-2 positive elderly breast cancer

Objective To investigate the clinical efficacy and safety of combined treatment with trastuzumab, carboplatin and docetaxel in HER-2 positive elderly breast cancer. Methods The selection of HER-2 positive elderly breast cancer patients in the control group was limited to June 2016 to May 2017. 58 patients were enrolled in the control group and treated with carboplatin plus docetaxel. The study group was HER. The selection time of -2 positive elderly breast cancer patients was limited to June 2017 to May 2018. The 58 patients admitted to the study group were treated with trastuzumab, carboplatin and docetaxel. Results In the comparison of total effective rate and total effective rate of pathological effect, the study group was higher than the control group. There was no significant difference in the incidence of adverse events between the two groups. The CRP value of the study group after treatment was smaller than that of the control group. Conclusion The combination of trastuzumab, carboplatin and docetaxel in HER-2 positive elderly breast cancer patients can improve their clinical outcomes, and the dosage of patients is still within the safety range.